Ultragenyx Pharmaceutical Inc.

NasdaqGS:RARE 株式レポート

時価総額：US$5.0b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Ultragenyx Pharmaceutical 将来の成長

Future 基準チェック /26

Ultragenyx Pharmaceutical利益と収益がそれぞれ年間50%と32%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-62.1% 50.9%なると予測されています。

主要情報

50.7%

収益成長率

53.0%

EPS成長率

Biotechs 収益成長28.5%
収益成長率30.9%
将来の株主資本利益率-55.3%
アナリストカバレッジ

Good

最終更新日26 Sep 2024

今後の成長に関する最新情報

Recent updates

We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

Sep 04
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective

Aug 22

There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump

Aug 03
There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump

Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being

Jun 12
Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being

Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching

Jun 06

We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

May 24
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet

Mar 09

Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?

Feb 01
Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?

There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise

Dec 28
There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise

Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?

Sep 12
Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?

An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued

May 24
An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued

Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet

Apr 17
Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate

Feb 18
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate

Ultragenyx upgraded to buy at Guggenheim as stock trading at discount to biotech peers

Oct 13

Ultragenyx grants stock options, restricted stock units

Oct 05

Ultragenyx Pharmaceuticals: Downward Trajectory Likely To Continue

Sep 02

業績と収益の成長予測

NasdaqGS:RARE - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/2026848-337-235-32116
12/31/2025625-495-293-33420
12/31/2024537-553-413-36919
6/30/2024481-585-492-469N/A
3/31/2024443-613-544-509N/A
12/31/2023434-607-522-475N/A
9/30/2023410-635-553-481N/A
6/30/2023403-721-553-459N/A
3/31/2023384-719-529-420N/A
12/31/2022363-707-527-380N/A
9/30/2022343-678-480-344N/A
6/30/2022334-506-438-309N/A
3/31/2022332-470-416-297N/A
12/31/2021351-454-412-339N/A
9/30/2021360-356-426-347N/A
6/30/2021359-351-411-349N/A
3/31/2021334-204-243-196N/A
12/31/2020271-187-176-132N/A
9/30/2020215-256-175-142N/A
6/30/2020159-301-203-168N/A
3/31/2020122-425-381-345N/A
12/31/2019104-403-370-345N/A
9/30/201984-397-344-329N/A
6/30/201970-371-320-310N/A
3/31/201959-325-304-297N/A
12/31/201851-198-295-291N/A
9/30/201838-192-320-317N/A
6/30/201826-183-313-309N/A
3/31/201813-204N/A-282N/A
12/31/20173-302N/A-254N/A
9/30/20170-292N/A-220N/A
6/30/20170-277N/A-186N/A
3/31/20170-261N/A-177N/A
12/31/20160-246N/A-161N/A
9/30/20160-230N/A-154N/A
6/30/20160-204N/A-156N/A
3/31/2016N/A-177N/A-133N/A
12/31/2015N/A-146N/A-106N/A
9/30/2015N/A-107N/A-78N/A
6/30/2015N/A-84N/A-58N/A
3/31/2015N/A-68N/A-52N/A
12/31/2014N/A-65N/A-45N/A
9/30/2014N/A-67N/A-42N/A
6/30/2014N/A-63N/A-38N/A
3/31/2014N/A-61N/A-36N/A
12/31/2013N/A-50N/A-31N/A

アナリストによる今後の成長予測

収入対貯蓄率: RARE今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: RARE今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: RARE今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: RAREの収益 ( 32% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: RAREの収益 ( 32% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: RARE 3 年以内に赤字になると予測されています。

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y